Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-Dense FEC Followed by Paclitaxel in Primary Breast Cancer
NCT02225652Phase 2Completed
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori"
- Start
- Sep 2010
- Primary completion
- Sep 2013
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of fluorouracil, epirubicin, cyclophosphamide, paclitaxel in breast cancer, sponsored by Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori". Started Sep 2010; status: completed.
02
Drugs
fluorouracilepirubicincyclophosphamidepaclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02225652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02225652.